A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
Gynecol Oncol
; 151(2): 374-380, 2018 11.
Article
em En
| MEDLINE
| ID: mdl-30213435
ABSTRACT
The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias dos Genitais Femininos
/
Imunoterapia
Tipo de estudo:
Sysrev_observational_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Gynecol Oncol
Ano de publicação:
2018
Tipo de documento:
Article